Target intelligence / Profile preview

ELL-associated factor 1 (EAF1)

Target
EAF1
Molecular classification
Transcription factor (specifically, a transcription elongation factor), Nuclear protein
01

Overview

ELL-associated factor 1 (EAF1) is a transcription elongation factor that partners with the RNA polymerase II elongation factor ELL to modulate gene expression. It regulates transcription elongation, cellular proliferation, differentiation, and hormone signaling by forming multiprotein complexes and interacting with critical transcriptional machinery. EAF1 acts as a tumor suppressor in prostate epithelial cells, and its disruption is implicated in the development of acute myeloid leukemia via oncogenic fusion proteins (MLL-ELL and MLL-EAF1). EAF1 also plays a role in embryogenesis, cell fate decision, and erythroid differentiation through c-Myb and Wnt signaling pathways

Other names
EAF1ELL-associated factor 1ELL (eleven nineteen lysine-rich leukemia gene)-associated factor 1
02

Mechanism of action

No drugs directly target EAF1. In the context of disease, targeting EAF1 could theoretically impact transcriptional regulation, oncogenic fusion proteins, or cell differentiation—but mechanisms remain experimental or unknown.

03

Biological functions

Regulation of transcription elongation by RNA polymerase IIModulation of gene expressionTumor suppression in prostate epithelial cellsRegulation of cell fate during embryogenesisControl of erythroid differentiation via Wnt signalingRegulation of steroid receptor responses and hormone signalingPart of transcriptional complexes (e.g., interacting with ELL, EAF2, and MLL fusion proteins)
04

Disease associations

Cancer (especially prostate and acute myeloid leukemia)Leukemia (implicated in MLL-ELL and MLL-EAF1 fusion proteins)Inflammation (via effects on epithelial homeostasis)Disrupted in HIV-1 infection (negative regulation)
05

Safety considerations

There are no notable safety concerns documented for direct targeting of EAF1, primarily because no therapeutics currently target it.However, modulation could theoretically impact core transcriptional functions and cell differentiation pathways.
06

Biomarkers

EAF1 expression level may serve as a biomarker in prostate cancer progression (frequently down-regulated in advanced cancer)potentially in acute myeloid leukemia for MLL fusion proteins

Beyond the preview

Go deeper on ELL-associated factor 1 (EAF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELL-associated factor 1 (EAF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call